

Molekulare Diagnostik und Pathophysiologie: Beispiele aus Hämatopoese, aus der Antigendiagnostik von Blutzellen und aus der Hämostaseologie

- 1) Deutscher Bundestag Drucksache 16/12000, Bericht des Ausschusses für Bildung, Forschung und Technikfolgenabschätzung. Zukunftsreport Individualisierte Medizin und Gesundheitssystem (<http://dip21.bundestag.de/dip21/btd/16/120/1612000.pdf>) 2009.
- 2) Heimpel H, Wendt F. Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of erythroblasts. *Helv Med Acta.* 1968 ; **34**:103-115.
- 3) Crookston JH, Crookston MC, Burnie KL, et al. Hereditary erythroblastic multinuclearity associated with a positive acidified-serum test: a type of congenital dyserythropoietic anaemia. *Br J Haematol.* 1969; **17**:11-26.
- 4) Wickramasinghe SN. Congenital dyserythropoietic anaemias: clinical features, haematological morphology and new biochemical data. *Blood Rev.* 1998;**12**:178-200.
- 5) Delaunay J, Iolascon A. The congenital dyserythropoietic anaemias. *Baillieres Best Pract Res Clin Haematol.* 1999;**12**:691-705.
- 6) Heimpel H, Iolascon, A. Congenital dyserythropoietic anemia in Disorders of homeostasis, erythrocytes, erythropoiesis (eds. Beaumont, C., Beris, Ph., Beuzard, Y. & Brugnara, C.) 178-201 (European School of Haematology, Paris, 2009).
- 7) Heimpel H, Anselstetter V, Chrobak L, et al. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. *Blood.* 2003;**102**:4576-4581.
- 8) Heimpel H, Kellermann K, Neuschwander N, et al. The morphological diagnosis of congenital dyserythropoietic anemia: Results of a quantitative analysis of peripheral blood and bone marrow cells. *Haematologica.* Im Druck.
- 9) Queisser W, Spiertz E, Jost E, Heimpel H. Proliferation disturbances of erythroblasts in congenital dyserythropoietic anemia type I and II. *Acta Haematol.* 1971;**45**:65-76.
- 10) Denecke J, Kranz C, Nimtz M, et al. Characterization of the N-glycosylation phenotype of erythrocyte membrane proteins in congenital dyserythropoietic anemia type II (CDA II/HEMPAS). *Glycoconj J.* 2008 ;**25**:375-382.
- 11) Schwarz K, Iolascon A, Verissimo F, et al. Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. *Nat Genet.* 2009;**41**:936-40.
- 12) Bianchi P, Fermo E, Vercellati C, et al. Congenital dyserythropoietic anemia type II (CDAll) is caused by mutations in the SEC23B gene. *Hum Mutat.* 2009;**30**:1292-1298.
- 13) Iolascon A, Russo R, Esposito MR, et al. Molecular analysis of forty two CDAll patients: New mutations in the SEC23B gene. Search for a genotype-phenotype relationship. *Haematologica,* Im Druck.
- 14) Daniels G, Reid ME. Blood groups: the past 50 years. *Transfusion* 2010; **50**:281-289.
- 15) Daniels G. et al. International Society of Blood Transfusion committee on terminology for red cell surface antigens: Macao report. *Transfusion* 2009;**96**:153-156.
- 16) Westhoff CM. Molecular testing for transfusion medicine. *Current Opinion in Hematology* 2006;**13**: 471-475.
- 17) Reid ME. Applications in DNA-based assays in blood group antigen and antibody identification. *Transfusion* 2003; **43**:1748-1757.
- 18) Flegel WA. Blood group genotyping in Germany. *Transfusion* 2007; **47**:47S-53S.
- 19) Veldhuisen B, van der Schoot, CE, de Haas GM. Blood group genotyping: from patient to high throughput donor screening. *Vox Sanguinis* 2009; **97**:198-206.
- 20) Quill E. Blood-matching goes genetic. *Science* 2008; **319**:1478-1479.
- 21) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) Deutscher Ärzte-Verlag 2007 (ISBN 978-3-7691-1250-4).



- 22) Avent ND et al. The BloodGen project: toward mass-scale comprehensive genotyping of blood donors in the European Union and beyond. *Transfusion* 2007; **47**:40S-46S.
- 23) Hashmi G. Red blood cell antigen phenotype by DNA analysis. *Transfusion* 2007; **47**:60S-63S.
- 24) Wagner FF, Döscher A, Bittner R, Petershofen EK. Identifying donors with specific antigen combinations by multiplex PCR and pooled capillary electrophoresis [abstract]. *Transfus Med Hemother* 2007; **34** (Suppl. 1).
- 25) Wagner FF, Bittner R, Petershofen EK, Döschner A, Müller TH. Cost-efficient sequence-specific priming-polymerase chain reaction screening for blood donors with rare phenotypes. *Transfusion* 2008; **48**:1169-1173.
- 26) Grootker-Tax MG, Soussan AA, de Haas M, Maaskant-van Wijk PA, van der Schoot CE. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. *Transfusion* 2006; **46**:2142-2148.
- 27) Legler TJ et al. Prediction of fetal RhD and Rh CcEe phenotype from maternal plasma with real-time polymerase chain reaction. *Transfus Apher Sci* 2002; **27**:217-23.
- 28) Grootker-Tax MG, Maaskant-van Wijk PA, van Drunen J., van der Schoot CE. The highly variable **RH** locus in non-white persons hampers **RHD** zygosity determination but yields more insight into RH-related evolutionary events. *Transfusion* 2005; **45**:327-337.
- 29) Flegel WA. How I manage donors and patients with a weak D phenotype. *Current Opinion in Hematology* 2006; **13**:476-483.
- 30) Flegel WA, von Zabern I, Wagner FF. Six year's experience performing **RHD** genotyping to confirm D- red blood cell units in Germany for preventing anti-D immunizations. *Transfusion* 2009; **49**:465-71.
- 31) Daniels G. Functions of red cell surface proteins. *Vox Sanguinis* 2007; **93**:331-340.
- 32) Mohandas N, Gallagher PG. Red cell membrane: past, present, and future. *Blood* 2008; **112**:3939-3948.
- 33) Bessler M, Schaefer A, Keller P. Paroxysmal nocturnal hemoglobinuria: insights from recent advances in molecular biology. *Transfus Med Rev* 2001; **15**:255-267.
- 34) Nydegger UE et al. Histo-blood group antigens as allo- and autoantigens. *Ann N Y Acad Sci* 2005; **1050**:40-51.
- 35) Greinacher A, Bux J, Salama A. Autoimmune Thrombozytopenie, Neutropenie und Hämolysse. *Internist* 2009; **50**:276-290.
- 36) Ouwehand WH, Navarrete C. The Molecular Basis of Blood Cell Alloantigens. In *Molecular Hematology*, 2nd edition, Provan D, Gribben JG (eds), Blackwell Publishing Ltd, 2007; 225-240.
- 37) Lucas GF, Metcalfe P. Platelet and granulocyte glycoprotein polymorphisms. *Transfus Med* 2000; **10**:157-174.
- 38) Nguyen XD, Dugrillon A, Beck C, Kerowgan M, Klüter H. A novel method for simultaneous analysis of specific platelet antibodies: SASPA. *Br J Haematol* 2004; **127**:552-560.
- 39) Curtis BR. Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders. *Semin Thromb Hemost* 2008; **34**:539-548.
- 40) Hurd CM, Cavanagh G, Schuh A, Ouwehand WH, Metcalfe P. Genotyping for platelet-specific antigens: techniques for the detection of single nucleotide polymorphisms. *Vox Sang* 2002; **83**:1-12.
- 41) Bugert P, Lese A, Meckies J, Zieger W, Eichler H, Klüter H. Optimized sensitivity of allele-specific PCR for prenatal typing of human platelet alloantigen single nucleotide polymorphisms. *Biotechniques* 2003; **35**:170-174.
- 42) McBride S. Real-Time PCR assays for high-throughput human platelet antigen typing. In *DNA and RNA profiling in human blood*, Bugert P (ed), Humana Press, Totowa, NJ. *Methods in Molecular Biology* 2009; **496**:39-49.
- 43) Bugert P, McBride S, Smith G, Dugrillon A, Klüter H, Ouwehand WH, Metcalfe P. Microarray based genotyping for blood groups; comparison of gene array and nuclease assay techniques using HPA as a model. *Transfusion* 2005; **45**:654-659.
- 44) Bux J. Human neutrophil alloantigens. *Vox Sang* 2008; **94**:277-285.





- 45) Nguyen XD, Flesch B, Sachs UJ, Kroll H, Klüter H, Müller-Steinhardt M. Rapid screening of granulocyte antibodies with a novel assay: Flow cytometric granulocyte immunofluorescence test. *Transfusion* 2009; **49**: 2700-2708.
- 46) Greinacher A, Wesche J, Hammer E, Füll B, Völker U, Reil A, Bux J. Characterization of the human neutrophil alloantigen-3a. *Nat Med* 2010; **16**: 45-48.
- 47) Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factor VIII and IX. *Haemophilia* 2006, 12 (Suppl. 6), 15-22.
- 48) Schneppenheim R (2004). Molecular genetics of von Willebrand disease. *Hamostaseologie*; **24**:37-43.
- 49) Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. *Lancet* 1996; **348**: 432-438.
- 50) Geisen C, Watzka M, Sittlinger K et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnic variability of oral anticoagulation. *Thromb Haemost* 2005; **94**: 773-779.
- 51) Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *N Engl J Med* 2005; **352**: 2285-2293.
- 52) Yuan HY, Chen JJ, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. *Hum Mol Genet* 2005; **14**: 1745-1751.
- 53) Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. *Nature* 2004; **427**: 537-541.
- 54) Oldenburg J, Bevans CG, Fregin A, Geisen C, et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. *Thromb Haemost* 2007; 98(3): 570-8.
- 55) Reid ME, Lomas-Francis C. *The blood group Antigen FactsBook*. Elsevier 2002 (ISBN 0-12-586585-6).
- 56) Daniels G. *Human blood groups*. Blackwell 2002 (ISBN 0-632-056460).
- 57) Daniels G. *The molecular genetics of blood group polymorphism*. *Hum Genet* 2009; **126**:729-742.
- 58) Daniels G. *Structure and function of red cell surface antigens*. *ISBT Science Series* 2006;1: 3-8.

Gegebenenfalls weiterführende Links

- 1) Blood group mutation database: www.bioc.aecom.yu.edu/bgmut/index.htm
- 2) RhesusBase: www.uni-ulm.de/~wfliegel/RH/
- 3) Arbeitsgemeinschaft "Seltene Blutgruppen" der Sektion V (Immunhämatologie/Gentechnik) der DGTI: www.seltene-blutgruppen.de

